Drugs / POM3
POM3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT00746811 | Jan → Jul 2010 | hyperlipoproteinemia | Provident Clinical Research | Completed | Missed primary |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT01034540 | Mar → Dec 2010 | hypertriglyceridemia | Provident Clinical Research | Completed | Missed primary |
| — | NCT00504309 | Jul 2007 → Jan 2009 | hypertriglyceridemia | Penn State University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POM3 | “prescription omega-3-acid ethyl esters (POM3, 4 g/day) versus placebo (soy oil)” PMID 21297494 ↗ Apr 2011 |
| Known as | Omega-3 acid ethyl esters | “4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention” NCT00504309 ↗ |
| Known as | prescription omega-3-acid ethyl esters | “prescription omega-3-acid ethyl esters (POM3, 4 g/day) versus placebo (soy oil)” PMID 21297494 ↗ Apr 2011 |